Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo.
about
Investigations into the auto-FAT10ylation of the bispecific E2 conjugating enzyme UBA6-specific E2 enzyme 1Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseasesIncreased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 MiceRegulation of HIV-Gag expression and targeting to the endolysosomal/secretory pathway by the luminal domain of lysosomal-associated membrane protein (LAMP-1) enhance Gag-specific immune response.Conjugation of the ubiquitin activating enzyme UBE1 with the ubiquitin-like modifier FAT10 targets it for proteasomal degradation.Just one position-independent lysine residue can direct MelanA into proteasomal degradation following N-terminal fusion of ubiquitin.The search for animal models for Lassa fever vaccine developmentVaccine Platforms to Control Arenaviral Hemorrhagic FeversRegulation of protein synthesis and autophagy in activated dendritic cells: implications for antigen processing and presentation.The Biology and Underlying Mechanisms of Cross-Presentation of Exogenous Antigens on MHC-I Molecules.Demyelination during multiple sclerosis is associated with combined activation of microglia/macrophages by IFN-γ and alpha B-crystallin.Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins.Acute Pharmacologic Degradation of a Stable Antigen Enhances Its Direct Presentation on MHC Class I Molecules.Newly translated proteins are substrates for ubiquitin, ISG15, and FAT10.Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8 T Cell ResponsesThe structure of the ubiquitin-like modifier FAT10 reveals an alternative targeting mechanism for proteasomal degradation
P2860
Q24337322-7B79A2A2-E91E-4365-AC49-D4B21CAC935EQ30209342-72E85DFA-07E8-4380-96CA-19EFD9A307FDQ30392456-E3F82D88-0B58-41CF-86B4-156D6E3B8F86Q33763297-4C1562A7-0254-47F8-BEA7-403B6A0ECFBAQ34467024-3E695363-07BE-47F4-B9AC-56848698711EQ34581001-F60FF80A-8ACF-484C-94A6-CDEC8EBC9B61Q36588064-86C14B83-B6CF-4F09-BF74-C536BC5C2666Q36612929-27644A48-7509-4581-AE77-DB896CBA9C2FQ38869709-098FB428-1262-4CFB-B15A-293D7F69E9CEQ39104926-73B708A6-3A4E-4DB7-8F80-23D7D8BCACACQ44587763-0953B344-3522-4419-A219-0AB212C4C8F6Q47244680-42A632C0-D497-40E7-8C61-2C8CB5CA13FDQ47718257-361D6AE5-9CEF-4302-A120-8486E5492752Q51281230-8DD20CD9-3954-4DBA-B08D-64B2655C2D82Q57292428-A5C633CB-0FD3-4E95-9C07-C763EAA17F4CQ58737408-7F132FD8-D396-4A61-B3FC-943F4E71BAFC
P2860
Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Stable antigen is most effecti ...... binant vaccinia virus in vivo.
@en
Stable antigen is most effecti ...... binant vaccinia virus in vivo.
@nl
type
label
Stable antigen is most effecti ...... binant vaccinia virus in vivo.
@en
Stable antigen is most effecti ...... binant vaccinia virus in vivo.
@nl
prefLabel
Stable antigen is most effecti ...... binant vaccinia virus in vivo.
@en
Stable antigen is most effecti ...... binant vaccinia virus in vivo.
@nl
P2093
P2860
P356
P1433
P1476
Stable antigen is most effecti ...... binant vaccinia virus in vivo.
@en
P2093
Annegret Bitzer
Christopher Schliehe
Maries van den Broek
P2860
P304
P356
10.1128/JVI.00694-12
P407
P577
2012-07-03T00:00:00Z